Vial Neurology CRO is a tech-enabled CRO that delivers next-generation clinical trial management services. Vial's eSource and EDC technology platforms connect the entire trial process, resulting in faster and more efficient trials. Vial's services help accelerate the development of new devices and therapies.
Vial's goal is to empower scientists to find the most effective ways to treat all human diseases. The company's innovative technology platform, site networks, and operational excellence enable the organization to meet these goals. Vial currently employs more than 125 people and has contributed to over 750 clinical trials. Its centralized office is located in San Francisco. The company's innovative approach to recruitment has led to increased efficiency and patient recruitment.
Vial has recently expanded its oncology expertise. It has hired Dr. Neeraj Agarwal to join its scientific advisory board and use his experience to improve clinical trials. Agarwal has extensive experience in clinical research, serving as a senior director of clinical research innovation at Huntsman Cancer Institute and as a consultant to the FDA's Oncology Drug Advisory Committee. He also leads the SWOG Cancer Research Network's early therapeutics program.
Precision in neurology research is an approach that can help physicians develop more effective treatments for patients with neurodegenerative and neuropsychiatric disorders. But, it requires more sophisticated tools than simple genetic markers.
To succeed, it must integrate genomics data, clinical phenotype data, and human biology to determine druggable targets. Precision in neurology may be possible, thanks to a new toolbox of advanced techniques and technologies.
The availability of reliable genetic and phenotypic information for the development of a novel drug for neurodevelopmental disorders has posed a major challenge for research. Currently, there is no standardized way to determine the cause of a neurodevelopmental disorder, and diagnostic endorsement is often subjective and based on expert opinion.
Additionally, because the clinical picture of neurodevelopmental disorders can change over time, the availability of reliable information is limited. Additionally, the lack of appropriate preclinical models poses another hurdle for the development of novel therapies for neurodevelopmental disorders. However, the advent of human-induced pluripotent stem cell technology may solve these issues.
The market for neurology contract research organizations has grown significantly due to the growing focus on neurological disorders. For example, the Parkinson's Foundation's Parkinson's Prevalence Project estimates that one million Americans will have the disease by the year 2030. This increase in focus on neurological disorders is expected to continue to boost the market for neurology CROs.
QPS is a GLP/GCP-compliant CRO that offers a full range of drug discovery, preclinical, and clinical services to biotechnology, Pharma, and medical device companies. It is located in the US, Europe, and Asia, and has over 1150 employees. Its services encompass Neuropharmacology, Translational Medicine, and Toxicology.
It has a number of clinical facilities across North America, Europe, India, and Asia, as well as 30+ regional laboratories. Throughout its history, QPS has successfully conducted over 580 clinical trials involving more than 50,000 patients. It has been accredited by the Association for Accreditation of Human Research Protection Programs (AAHRPP), a global organization with rigorous standards.
Neurological Clinical Research Institute (NCRI) is a contract research organization that specializes in speeding up drug development for neurological disorders. It collaborates with NeuroNEXT to conduct clinical trials of novel treatments for neurological disorders.
NCRI provides outsourced research services to pharmaceutical, biotechnology, and medical device companies. The organization also performs research for academic institutions. According to Persistence Market Research, the neurology-focused CRO market is forecast to reach $1,479 million in 2021.
NCRI provides high-quality, multi-center neurology clinical trials. The company focuses on developing innovative observational and interventional trials for neurological disorders. NCRI also develops and implements software programs and platforms to improve the efficiency of clinical trials.
As a privately owned CRO, PharPoint is dedicated to helping pharmaceutical companies develop promising new medications. Its staff of talented and experienced professionals knows the importance of timely deliverables and exceptional quality. This is reflected in the excellent repeat client rates, the company enjoys. The company maintains offices in Wilmington and Durham, NC.